U.S. Government's AI Action Plan Praised by Tevogen.AI; Company Affirms Push to Speed Up AI Development in Healthcare Sector
Tevogen's PredicTcell™ Accelerates Immunotherapy Research
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has made a significant stride in the healthcare industry with the development of its proprietary AI-driven target discovery platform, PredicTcell™. As of mid-July 2025, the alpha version of PredicTcell™ has been deployed, marking a milestone in its journey to revolutionize immunotherapy research.
PredicTcell™ is designed to drastically reduce the time for target analysis in immunotherapy research, a move that could save billions in drug development costs. This groundbreaking platform has the potential to cut weeks off immunotherapy target analysis, a factor that aligns with the White House's AI Action Plan for healthcare.
In a bid to expand PredicTcell™'s capabilities, Tevogen plans to integrate it with Tevogen.AI. This integration will incorporate patient electronic health records and real-world data, aiming to enhance patient matching for clinical trials based on medical histories and demographics. This move supports the ExacTcell™ pipeline development and improves clinical trial efficiency, scalability, and inclusivity.
Partnering with Microsoft and Databricks has been key for this development, enabling the data handling and AI analytics infrastructure required for PredicTcell™'s operation. Tevogen.AI seeks scalable, ethical solutions that expand access to affordable, advanced therapeutics for all Americans.
The development of PredicTcell™ aligns with the healthcare priorities of the U.S. AI Action Plan, which emphasizes establishing domain-specific standards, regulatory sandboxes, and stakeholder convenings for AI in healthcare. However, it's important to note that the press release contains forward-looking statements regarding Tevogen's plans, expectations, and development of product candidates for the treatment of infectious diseases and cancer. Factors such as the need to raise additional capital, changes in markets, economic conditions, and regulatory changes may affect Tevogen's actual results.
For more information about Tevogen Bio Communications, please contact [email protected] or call 1 877 TEVOGEN, Ext 701. The press release was provided by GlobeNewswire via QuoteMedia.
Artificial-intelligence, technology: The integration of PredicTcell™ with Tevogen.AI will allow for the utilization of artificial intelligence to process patient electronic health records and real-world data, demonstrating the commitment to advanced technology in expanding capabilities and enhancing patient matching for clinical trials. This move is part of Tevogen's strategic plan to develop scalable, ethical solutions using technology, aiming to make advanced therapeutics accessible and affordable for all Americans.
